Previous Article | Next Article 
Journal of Bacteriology, December 1999, p. 7566-7570, Vol. 181, No. 24
0021-9193/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Gradual Alterations in Cell Wall Structure and
Metabolism in Vancomycin-Resistant Mutants of
Staphylococcus aureus
Krzysztof
Sieradzki and
Alexander
Tomasz*
The Rockefeller University, New York, New
York 10021
Received 8 July 1999/Accepted 29 September 1999
 |
ABSTRACT |
In five vancomycin-resistant laboratory step mutants selected from
the highly and homogeneously methicillin-resistant Staphylococcus aureus strain COL (MIC of methicillin, 800 µg/ml; MIC of
vancomycin, 1.5 µg/ml), the gradually increasing levels of resistance
to vancomycin were accompanied by parallel decreases in the levels of
methicillin resistance and abnormalities in cell wall metabolism. The
latter included a gradual reduction in the proportion of highly
cross-linked muropeptide species in peptidoglycan, down-regulation of
the production of penicillin-binding protein 2A (PBP2A) and PBP4, and
hypersensitivity to
-lactam antibiotics each with a relatively
selective affinity for the various staphylococcal PBPs; the
PBP2-specific inhibitor ceftizoxime was particularly effective.
 |
INTRODUCTION |
The mechanism of resistance in the
recently described glycopeptide-resistant clinical isolates of
Staphylococcus aureus is not well understood. A laboratory
mutant, VM50 (formerly called VM), with high-level resistance to
vancomycin (MIC, 100 µg/ml) and selected from the
methicillin-resistant S. aureus strain COL through several
steps of exposure to vancomycin, showed several unusual properties. The
most striking was a massive reduction in the level of methicillin
resistance, from an MIC of 800 µg/ml for the parental strain to an
MIC of 1.5 µg/ml for mutant VM50. This decrease paralleled an
increase in the vancomycin MIC from 1.5 µg/ml for the parental strain
COL to 100 µg/ml for the mutant (9). Evidence was also
obtained for the extensive perturbation of cell wall metabolism in
mutant VM50, including a reduction of the highly oligomeric muropeptide
components of the peptidoglycan and inactivation of penicillin-binding
protein 2A (PBP2A) and PBP4 (11, 12).
The mechanism of resistance in this laboratory mutant most likely
involves the accumulation of point mutations. In an effort to better
understand the nature of these mutations, we undertook to characterize
the four low- and intermediate-level-resistance step mutants VM3, VM6,
VM12, and VM25, which were the precursors of the already characterized
highly vancomycin-resistant mutant VM50.
 |
MATERIALS AND METHODS |
Bacterial strains and growth conditions.
The strains used in
this study are listed in Table 1. All
strains were grown in tryptic soy broth (TSB) (Difco, Detroit, Mich.)
at 37°C with aeration. Growth was monitored by measuring the optical
density at 620 nm with an LKB spectrophotometer (Pharmacia LKB
Biotechnology, Inc., Uppsala, Sweden). Viable titers and antibiotic resistance levels (population analysis) were determined by plating diluted cultures on tryptic soy agar (TSA) (Difco) as described before
(13). The plates were incubated at 37°C for 96 h.
Mutant isolation.
The lowest-level step mutant, VM3, was
isolated from a synergy plate containing methicillin plus a sub-MIC
concentration of vancomycin (9). Subsequent step mutants
with increasing levels of vancomycin resistance were isolated by
picking rare colonies that were capable of growth on agar containing
vancomycin at concentrations above the MIC for the majority of the
cells. Such colonies were then used as inocula of overnight cultures of
TSB supplemented with the same concentration of the antibiotic as the
agar plate from which the colony was picked.
Sequencing of mecA and pbp4 genes.
DNA fragments including the mecA and pbp4 genes
were amplified by PCR from chromosomal DNA and sequenced as described
before (11, 12).
Isolation of RNA and Northern blot hybridization.
Overnight
cultures were inoculated into fresh TSB and grown to the mid-log phase
(optical density,
0.7). RNA was extracted by use of a FastRNA Blue
isolation kit (Bio 101, Inc., Vista, Calif.) according to the
manufacturer's recommendations. After the concentration was adjusted
with a Gene Quant spectrophotometer (Pharmacia), RNA (5 µg) was
resolved by electrophoresis on 1.2% agarose-0.66 M formaldehyde gels
in morpholinepropanesulfonic acid (MOPS) running buffer. Blotting of
RNA onto Hybond N+ membranes (Amersham, Arlington Heights,
Ill.) was performed with the Turbo Blotter Neutral Transfer System
(Schleicher & Schuell, Inc., Keene, N.H.). For detection of specific
transcripts, DNA probes were labeled with [
-32P]dCTP
(Amersham) and hybridized under high-stringency conditions. The blots
were subsequently washed and autoradiographed.
Membrane purification and analysis of PBPs.
Membranes were
prepared from cells grown to the late exponential stage as described
previously (11), and then proteins (80 µg per sample) were
labeled with [3H]benzylpenicillin NEP salt (87.4 mCi per
mg) (Merck & Co., Inc., Rahway, N.J.) for 10 min at 30°C. The
reaction was stopped by the addition of an excess of nonlabelled
benzylpenicillin. The labeled PBPs were resolved by the technique of
Laemmli (2) and visualized by fluorography.
Preparation of peptidoglycan and analysis.
Cell wall
peptidoglycan was prepared, and the muropeptide composition of
peptidoglycan was analyzed by reversed-phase high-performance liquid
chromatography (HPLC) as described before (1), except that
the alkaline phosphatase step was omitted.
Transductional crosses and analysis of transductants.
Crosses were performed with phage 80
as described previously
(6) with mutant VM50 as a recipient and RUSA4 and RUSA130 as
donor strains. Transductants were screened as described before (10).
 |
RESULTS |
Gradual decrease in the methicillin MICs for vancomycin-resistant
step mutants.
Figure 1 illustrates
the antibiotic susceptibility profiles of the methicillin-resistant
S. aureus parental strain COL and its five
vancomycin-resistant mutant derivatives for two antimicrobial agents,
vancomycin and methicillin. Overnight cultures of the bacteria were
plated at various dilutions on TSA supplemented with increasing
concentrations of either methicillin or vancomycin in the concentration
ranges indicated in Fig. 1. The right panel of Fig. 1 shows the gradual
decrease in the degree of methicillin resistance of mutant strains VM3,
VM6, VM12, VM25, and VM50 (formerly called VM). For the most highly
vancomycin-resistant strain, VM50, capable of growing in the presence
of 50 µg of vancomycin per ml, the highest concentration of
methicillin on which the majority of these bacteria was capable of
forming colonies was about 0.75 µg/ml. Gradually increasing
vancomycin MICs for mutants VM3 through VM50 are shown in the left
panel of Fig. 1. The great majority of cells in cultures of VM50 were
still capable of forming colonies on 50 µg of vancomycin per ml, but
no survivors were detected (less than 10
8) on agar
containing 100 µg of vancomycin per ml.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 1.
Phenotypic expression of resistance to vancomycin (left)
and methicillin (right) in a series of vancomycin-resistant step
mutants. Bacterial cultures were grown in TSB to stationary phase and
plated at several dilutions on TSA containing various concentrations of
vancomycin or methicillin, as described for the method of population
analysis (13). Asterisks indicate colonies that served as
sources for higher-level step mutants.
|
|
Gradual decrease in the growth rate of vancomycin-resistant step
mutants.
Cultures of the parental strain COL and the five step
mutants VM3, VM6, VM12, VM25, and VM50 were grown in TSB at 37°C with aeration. Culture growth was monitored by the determination of optical
density. The doubling times of the vancomycin-resistant step mutants
increased gradually from 32 min for the parental strain COL to 50 min
for VM3, 60 min for VM6, 72 min for VM12, and 78 min for VM25 and VM50.
The slow growth rate and the general growth deficiency of
vancomycin-resistant mutant VM50 were evident by its small colony size
on solid medium (Fig. 2), which did not increase upon prolonged incubation.

View larger version (106K):
[in this window]
[in a new window]
|
FIG. 2.
Slow growth rate of mutant VM50. A mixture of mutant
VM50 and parental strain COL was plated on TSA and incubated for
72 h at 37°C. The large colonies represent the parental strain;
the small colonies represent the mutant.
|
|
Transcription of mecA.
The drastic reduction of
methicillin resistance in the most highly vancomycin-resistant mutant,
VM50, was recently shown to be associated with the inactivation of the
mecA gene (12). Sequencing of the mecA
region from the low- or intermediate-level-resistance step mutants VM3
through VM25 showed no evidence for sequence alterations (data not
shown). When total RNA from mutants VM3 through VM25 was hybridized
with the mecA probe in Northern blot analysis, a radioactive
band with a molecular size of 2 kb, corresponding to the size of the
mecA transcript, was detected in each preparation (Fig.
3). However, the intensity of this band
was significantly reduced only in mutants VM12 and VM25. Thus, the
gradually declining methicillin resistance level in these mutants seems
to be associated with the decreased transcription of mecA.

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 3.
Levels of mecA transcription in the parental
strain COL (lane 1) and the vancomycin-resistant step mutants VM3
through VM50 (lanes 2 to 6). RNA was extracted from mid-log-phase
cultures and resolved by electrophoresis on agarose-formaldehyde gels,
and mecA RNA was located after hybridization with a
32P-labeled mecA DNA probe as described in
Materials and Methods.
|
|
Expression of PBP4 in step mutants.
Plasma membrane
preparations isolated from the parental strain COL and the
vancomycin-resistant step mutants were tested by use of a fluorographic
assay with [3H]penicillin for the presence of
staphylococcal PBPs. Figure 4 shows that
there was a gradual decrease in the cellular amounts of PBP4 in mutants
VM3, VM6, VM12, and VM25 and a complete disappearance of PBP4 in mutant
VM50, in which the disruption of pbp4 was recently demonstrated (11). Sequencing of the pbp4 gene
and its promoter region from step mutants VM3 through VM25 did not
reveal any alterations (data not shown).

View larger version (74K):
[in this window]
[in a new window]
|
FIG. 4.
PBP patterns of parental strain COL (lane 1) and its
vancomycin-resistant derivatives VM3 (lane 2), VM6 (lane 3), VM12 (lane
4), VM25 (lane 5), and VM50 (lane 6). Purified plasma membranes were
incubated with [3H]benzylpenicillin and were subjected to
sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then
fluorography as described in Materials and Methods.
|
|
Changes in the muropeptide composition of peptidoglycan in
vancomycin-resistant step mutants.
Figure
5 shows the HPLC elution profiles of
enzymatic peptidoglycan hydrolysates prepared from the parental strain
COL and its five vancomycin-resistant mutant derivatives. Inspection of elution profiles shows that the gradual decrease in the relative proportions of the highly oligomerized muropeptides (peak 17 [a pentamer] and larger oligomers with retention times longer than that
of peak 17), seen on the HPLC profile as a "hump" of unresolved muropeptide species, parallels the increase in the vancomycin MICs for
the mutants. The numbers in Fig. 5 indicate muropeptides with
identified chemical structures (1).

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 5.
HPLC elution profiles of muropeptides isolated from the
parental strain COL and the vancomycin-resistant step mutants VM3
through VM50. Peptidoglycan was purified and digested with muramidase,
and the muropeptides were separated by HPLC as described in Materials
and Methods.
|
|
Hypersensitivity to
-lactams in strain VM50.
In order to
further explore the relationship between susceptibility to
-lactams
and that to vancomycin, the sensitivities of the parental strain COL
and mutant VM50 to a number of inhibitory
-lactams were compared.
The
-lactam compounds were chosen for their known preferential
affinities for the various staphylococcal PBPs (5). For
these experiments, it was necessary to construct a transductant
derivative (VM-RU4) in which the mecA gene of VM50 was
inactivated by a Tn551 insert so as to exclude the presence of the mecA gene product, PBP2A, which is known to provide
blanket resistance against all
-lactam antibiotics, thus preventing
the titration of normal PBP1 through PBP4 by appropriate
-lactam inhibitors. Table 2 clearly shows the
hypersensitivity of vancomycin-resistant mutant VM-RU4 to most
-lactam inhibitors tested. Particularly striking was the reduction
of the MIC of ceftizoxime, a
-lactam compound with a selective high
affinity for PBP2 (5), for the vancomycin-resistant mutant
from 3.0 µg/ml to 0.4 µg/ml. There was no reduction in the MIC of
cefoxitin.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
-Lactam susceptibility profiles of VM-RU4, a
derivative of vancomycin-resistant mutant VM50 with an interrupted
mecA gene
|
|
Effect of ceftizoxime on the expression of vancomycin
resistance.
To further test the possible involvement of PBP2 with
vancomycin resistance, the same selective inhibitors of the
staphylococcal PBPs were also tested for their effect on the expression
of vancomycin resistance. Figure 6 shows
that of all the
-lactam inhibitors used at 0.25× their respective
MICs, ceftizoxime was by far the most potent compound, causing a
reduction in the vancomycin MIC for strain VM50 from 100 µg/ml to
0.75 µg/ml, i.e., close to the MIC for the parental strain COL.
However, the population analysis profile generated by ceftizoxime was
heterogeneous, and bacteria capable of expressing at least partial
resistance to vancomycin in the presence of a sub-MIC concentration of
ceftizoxime were also present at frequencies of about 10
6
(Fig. 6A).

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 6.
Inhibitory effect of -lactams on the phenotypic
expression of vancomycin resistance in strain VM50 (A) and massive
reduction of vancomycin resistance in strain VM50 with inactivated PBP2
(B). (A) Cultures of VM50 grown in TSB overnight were plated at
different cell concentrations on TSA containing various concentrations
of vancomycin and one-fourth the MIC of -lactam antibiotics with
selective affinities for PBP1, PBP2, PBP3, and PBP4. (B) The
pbp2 gene in strain VM50 was inactivated by allele
replacement with strain RU130 (7) as described in Materials
and Methods. Open squares represent strain VM50 with inactivated PBP2
(VM-RU130); solid circles represent VM50 with the intact
pbp2 gene. Colonies were counted, and data were plotted to
provide population analysis profiles as described before
(13).
|
|
A similar, extensive inhibitory effect on the expression of vancomycin
resistance was observed for a derivative of VM50 in which the
pbp2 gene was inactivated by transduction with DNA from the
auxiliary mutant RU130, in which this gene is interrupted by a
Tn551 insertion (7). The vancomycin MIC for the
resulting transductant, VM-RU130, was reduced from 100 µg/ml to 1.5 µg/ml (Fig. 6B).
 |
DISCUSSION |
Expanding the study of the mechanism of vancomycin resistance in
S. aureus to the four low- to intermediate-level-resistance step mutants that are the precursors of the highly vancomycin-resistant mutant VM50 characterized earlier (9-11) provided new
insights into one of the most striking aspects of this mechanism,
namely, the apparent incompatibility between the optimal phenotypes of methicillin resistance and vancomycin resistance. The most striking feature observed in the four mutants, VM3, VM6, VM12, and VM25, was the
gradual and unidirectional change in several properties involved with
resistance to
-lactam antibiotics. These changes included a gradual
increase in doubling time, a gradual decrease in resistance to
methicillin, and a gradual reduction in the representation of the
highly cross-linked muropeptides in the peptidoglycan of the
vancomycin-resistant step mutants. Highly cross-linked muropeptides (i.e., oligomers including muropeptide 17 and components with higher
retention times), which represent over 60% of all muropeptide components in the parental strain COL (1), were decreased to 40% in strain VM6, 35% in VM25, and below 30% in VM50. Membrane preparations obtained from the mutants and evaluated for the relative concentrations of various staphylococcal PBPs showed a similar gradual
reduction in the quantity of PBP4, which was no longer detectable in
the most highly resistant mutant, VM50. Interruption of pbp4
in this mutant was described recently (11). No structural alteration in pbp4 could be detected in mutants VM3 through VM25.
Still another alteration in cell wall metabolism that paralleled the
increasing vancomycin resistance of the step mutants was detected when
the transcription of the mecA gene (the genetic determinant
of PBP2A) was evaluated by Northern analysis. Compared with that in the
parental strain COL, the mecA mRNA was clearly down-regulated in strains VM12 and VM25. In a recent study, it was
shown that in the most highly resistant mutant of this series, VM50,
PBP2A could no longer be detected by a fluorographic assay, and the
mecA determinant of VM50 was interrupted by a 19-bp
duplication which generated a stop codon at position 286 (12). No alteration in the mecA sequence was
detectable in mutants VM3 through VM25. Interestingly, Northern
analysis revealed the production of mecA mRNA in mutant VM50
in amounts comparable to those seen in the parental strain COL (Fig.
3).
The unidirectional change in the properties of the vancomycin-resistant
step mutants suggests a gradual "tuning down" of the transpeptidase
system of cell wall synthesis, beginning with the gradual reduction in
the amounts of PBP4 and decreased transcription of PBP2A and
culminating in the complete inactivation of both of these genes in the
most highly vancomycin-resistant mutant, VM50. The impact of the tuning
down of these two transpeptidases is apparent from the reduction of
highly cross-linked oligomeric components in the peptidoglycan.
The gradual and extensive decrease in the peptide network cross-linking
the staphylococcal peptidoglycan in the vancomycin-resistant mutants
suggests that some compensatory changes in other aspects of the cell
wall structure must occur to ensure the stability of the cell wall.
Preliminary evidence suggesting that such a compensatory change
involves the increased dependence of the vancomycin-resistant staphylococci on the glycan component of the cell wall comes from the
observation that the cell wall of mutant VM50 acquired relative resistance to lysostaphin and hypersensitivity to the action of the M1
murein hydrolase (11). The reduction in the MIC for the VM50
mutant of ceftizoxime, a selective inhibitor of PBP2, and the drastic
reduction in vancomycin resistance observed for cells exposed to
sub-MIC concentrations of ceftizoxime or inactivation of
pbp2 suggest that one of the PBPs that may acquire a major role in the assembly of the cell wall of vancomycin-resistant mutants
may be PBP2, a postulated bifunctional enzyme with both transpeptidase
and transglycosylase activities (4). Overexpression of PBP2
in glycopeptide-resistant mutants of S. aureus was described previously (8). Nevertheless, the results described in this communication indicate that not only ceftizoxime but also selective
-lactam inhibitors of PBP1 and PBP3 had significant inhibitory effects on strain VM50.
The tuning down of transpeptidases and the gradual reduction in the
proportion of the highly cross-linked muropeptides should shift the
composition of the cell wall of vancomycin-resistant staphylococci
toward enrichment of monomeric muropeptide components carrying the
intact D-ala-D-ala carboxy-terminal residues,
which are the known attachment sites for glycopeptide antibiotics. In recent publications, we summarized evidence suggesting that the increased capacity of such monomer-rich cell walls for capturing and
immobilizing glycopeptide molecules before they could reach cell wall
synthetic sites on the plasma membrane may be part of the mechanism of
glycopeptide resistance in S. aureus (10, 11).
 |
ACKNOWLEDGMENT |
This study received partial support from the Irene Diamond Fund.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: The Rockefeller
University, 1230 York Ave., New York, NY 10021. Phone: (212) 752-6159. Fax: (212) 327-8688. E-mail:
tomasz{at}rockvax.rockefeller.edu.
 |
REFERENCES |
| 1.
|
De Jonge, B. L. M.,
Y.-S. Chang,
D. Gage, and A. Tomasz.
1992.
Peptidoglycan composition of a highly methicillin-resistant Staphylococcus aureus strain: the role of penicillin binding protein 2A.
J. Biol. Chem.
267:11248-11254[Abstract/Free Full Text].
|
| 2.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature (London)
227:680-685[Medline].
|
| 3.
|
Matthews, P., and A. Tomasz.
1990.
Insertional inactivation of the mec gene in a transposon mutant of a methicillin-resistant clinical isolate of Staphylococcus aureus.
Antimicrob. Agents Chemother.
34:1777-1779[Abstract/Free Full Text].
|
| 4.
|
Murakami, K.,
T. Fujimura, and M. Doi.
1994.
Nucleotide sequence of the structural gene for the penicillin-binding protein 2 of Staphylococcus aureus and the presence of a homologous gene in other staphylococci.
FEMS Microbiol. Lett.
117:131-136[Medline].
|
| 5.
|
Okonogi, K.,
Y. Noji,
M. Nakao, and A. Imada.
1995.
The possible physiological roles of penicillin-binding proteins of methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
J. Infect. Chemother.
1:50-58.
|
| 6.
|
Oshida, T., and A. Tomasz.
1992.
Isolation and characterization of a Tn551-autolysis mutant of Staphylococcus aureus.
J. Bacteriol.
174:4952-4959[Abstract/Free Full Text].
|
| 7.
|
Pinho, M.,
A. M. Ludovice,
S. Wu, and H. de Lencastre.
1997.
Massive reduction in methicillin resistance by transposon inactivation of the normal PBP2 in a methicillin resistant strain of Staphylococcus aureus.
Microb. Drug Resist.
3:409-413[Medline].
|
| 8.
|
Shlaes, D. M.,
J. H. Shlaes,
S. Vincent,
L. Etter,
P. D. Fey, and R. V. Goering.
1993.
Teicoplanin-resistant Staphylococcus aureus expresses a novel membrane protein and increases expression of penicillin-binding protein 2 complex.
Antimicrob. Agents Chemother.
37:2432-2437[Abstract/Free Full Text].
|
| 9.
|
Sieradzki, K., and A. Tomasz.
1997.
Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus.
J. Bacteriol.
179:2557-2566[Abstract/Free Full Text].
|
| 10.
|
Sieradzki, K., and A. Tomasz.
1998.
Suppression of glycopeptide resistance in a highly teicoplanin resistant mutant of Staphylococcus aureus by transposon inactivation of genes involved in cell wall synthesis.
Microb. Drug Resist.
4:159-168[Medline].
|
| 11.
|
Sieradzki, K.,
M. G. Pinho, and A. Tomasz.
1999.
Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus.
J. Biol. Chem.
274:18942-18946[Abstract/Free Full Text].
|
| 12.
| Sieradzki, K., S. W. Wu, and A. Tomasz.
Inactivation of the methicillin resistance gene mecA in
vancomycin-resistant Staphylococcus aureus. Microb. Drug
Resist., in press.
|
| 13.
|
Tomasz, A.,
S. Nachman, and H. Leaf.
1991.
Stable classes of phenotypic expression in methicillin-resistant clinical isolates of staphylococci.
Antimicrob. Agents Chemother.
35:124-129[Abstract/Free Full Text].
|
Journal of Bacteriology, December 1999, p. 7566-7570, Vol. 181, No. 24
0021-9193/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Burgess, D. S., Rapp, R. P.
(2008). Bugs versus drugs: Addressing the pharmacist's challenge. Am J Health Syst Pharm
65: S4-S15
[Abstract]
[Full Text]
-
Noto, M. J., Fox, P. M., Archer, G. L.
(2008). Spontaneous Deletion of the Methicillin Resistance Determinant, mecA, Partially Compensates for the Fitness Cost Associated with High-Level Vancomycin Resistance in Staphylococcus aureus. Antimicrob. Agents Chemother.
52: 1221-1229
[Abstract]
[Full Text]
-
Amiali, N. M., Mulvey, M. R., Berger-Bachi, B., Sedman, J., Simor, A. E., Ismail, A. A.
(2008). Evaluation of Fourier transform infrared spectroscopy for the rapid identification of glycopeptide-intermediate Staphylococcus aureus. J Antimicrob Chemother
61: 95-102
[Abstract]
[Full Text]
-
Meehl, M., Herbert, S., Gotz, F., Cheung, A.
(2007). Interaction of the GraRS Two-Component System with the VraFG ABC Transporter To Support Vancomycin-Intermediate Resistance in Staphylococcus aureus. Antimicrob. Agents Chemother.
51: 2679-2689
[Abstract]
[Full Text]
-
Mwangi, M. M., Wu, S. W., Zhou, Y., Sieradzki, K., de Lencastre, H., Richardson, P., Bruce, D., Rubin, E., Myers, E., Siggia, E. D., Tomasz, A.
(2007). Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc. Natl. Acad. Sci. USA
104: 9451-9456
[Abstract]
[Full Text]
-
Fox, P. M., Climo, M. W., Archer, G. L.
(2007). Lack of Relationship between Purine Biosynthesis and Vancomycin Resistance in Staphylococcus aureus: a Cautionary Tale for Microarray Interpretation. Antimicrob. Agents Chemother.
51: 1274-1280
[Abstract]
[Full Text]
-
Perichon, B., Courvalin, P.
(2006). Synergism between {beta}-Lactams and Glycopeptides against VanA-Type Methicillin-Resistant Staphylococcus aureus and Heterologous Expression of the vanA Operon. Antimicrob. Agents Chemother.
50: 3622-3630
[Abstract]
[Full Text]
-
Renzoni, A., Barras, C., Francois, P., Charbonnier, Y., Huggler, E., Garzoni, C., Kelley, W. L., Majcherczyk, P., Schrenzel, J., Lew, D. P., Vaudaux, P.
(2006). Transcriptomic and Functional Analysis of an Autolysis-Deficient, Teicoplanin-Resistant Derivative of Methicillin-Resistant Staphylococcus aureus.. Antimicrob. Agents Chemother.
50: 3048-3061
[Abstract]
[Full Text]
-
McCallum, N., Karauzum, H., Getzmann, R., Bischoff, M., Majcherczyk, P., Berger-Bachi, B., Landmann, R.
(2006). In Vivo Survival of Teicoplanin-Resistant Staphylococcus aureus and Fitness Cost of Teicoplanin Resistance.. Antimicrob. Agents Chemother.
50: 2352-2360
[Abstract]
[Full Text]
-
Cooper, J. E., Feil, E. J.
(2006). The phylogeny of Staphylococcus aureus - which genes make the best intra-species markers?. Microbiology
152: 1297-1305
[Abstract]
[Full Text]
-
Yin, S., Daum, R. S., Boyle-Vavra, S.
(2006). VraSR Two-Component Regulatory System and Its Role in Induction of pbp2 and vraSR Expression by Cell Wall Antimicrobials in Staphylococcus aureus. Antimicrob. Agents Chemother.
50: 336-343
[Abstract]
[Full Text]
-
Cui, L., Lian, J.-Q., Neoh, H.-m., Reyes, E., Hiramatsu, K.
(2005). DNA Microarray-Based Identification of Genes Associated with Glycopeptide Resistance in Staphylococcus aureus. Antimicrob. Agents Chemother.
49: 3404-3413
[Abstract]
[Full Text]
-
Wootton, M., Bennett, P. M., MacGowan, A. P., Walsh, T. R.
(2005). Strain-Specific Expression Levels of pbp4 Exist in Isolates of Glycopeptide-Intermediate Staphylococcus aureus (GISA) and Heterogeneous GISA. Antimicrob. Agents Chemother.
49: 3598-3599
[Full Text]
-
Lu, J.-J., Lee, S.-Y., Hwa, S.-Y., Yang, A.-H.
(2005). Septic Arthritis Caused by Vancomycin-Intermediate Staphylococcus aureus. J. Clin. Microbiol.
43: 4156-4158
[Abstract]
[Full Text]
-
Leski, T. A., Tomasz, A.
(2005). Role of Penicillin-Binding Protein 2 (PBP2) in the Antibiotic Susceptibility and Cell Wall Cross-Linking of Staphylococcus aureus: Evidence for the Cooperative Functioning of PBP2, PBP4, and PBP2A. J. Bacteriol.
187: 1815-1824
[Abstract]
[Full Text]
-
Koehl, J. L., Muthaiyan, A., Jayaswal, R. K., Ehlert, K., Labischinski, H., Wilkinson, B. J.
(2004). Cell Wall Composition and Decreased Autolytic Activity and Lysostaphin Susceptibility of Glycopeptide-Intermediate Staphylococcus aureus. Antimicrob. Agents Chemother.
48: 3749-3757
[Abstract]
[Full Text]
-
Sieradzki, K., Tomasz, A.
(2003). Alterations of Cell Wall Structure and Metabolism Accompany Reduced Susceptibility to Vancomycin in an Isogenic Series of Clinical Isolates of Staphylococcus aureus. J. Bacteriol.
185: 7103-7110
[Abstract]
[Full Text]
-
Weigel, L. M., Clewell, D. B., Gill, S. R., Clark, N. C., McDougal, L. K., Flannagan, S. E., Kolonay, J. F., Shetty, J., Killgore, G. E., Tenover, F. C.
(2003). Genetic Analysis of a High-Level Vancomycin-Resistant Isolate of Staphylococcus aureus. Science
302: 1569-1571
[Abstract]
[Full Text]
-
Mongodin, E., Finan, J., Climo, M. W., Rosato, A., Gill, S., Archer, G. L.
(2003). Microarray Transcription Analysis of Clinical Staphylococcus aureus Isolates Resistant to Vancomycin. J. Bacteriol.
185: 4638-4643
[Abstract]
[Full Text]
-
Sieradzki, K., Leski, T., Dick, J., Borio, L., Tomasz, A.
(2003). Evolution of a Vancomycin-Intermediate Staphylococcus aureus Strain In Vivo: Multiple Changes in the Antibiotic Resistance Phenotypes of a Single Lineage of Methicillin-Resistant S. aureus under the Impact of Antibiotics Administered for Chemotherapy. J. Clin. Microbiol.
41: 1687-1693
[Abstract]
[Full Text]
-
Reipert, A., Ehlert, K., Kast, T., Bierbaum, G.
(2003). Morphological and Genetic Differences in Two Isogenic Staphylococcus aureus Strains with Decreased Susceptibilities to Vancomycin. Antimicrob. Agents Chemother.
47: 568-576
[Abstract]
[Full Text]
-
Schaaff, F., Reipert, A., Bierbaum, G.
(2002). An Elevated Mutation Frequency Favors Development of Vancomycin Resistance in Staphylococcus aureus. Antimicrob. Agents Chemother.
46: 3540-3548
[Abstract]
[Full Text]
-
Srinivasan, A., Dick, J. D., Perl, T. M.
(2002). Vancomycin Resistance in Staphylococci. Clin. Microbiol. Rev.
15: 430-438
[Abstract]
[Full Text]
-
Komatsuzawa, H., Ohta, K., Yamada, S., Ehlert, K., Labischinski, H., Kajimura, J., Fujiwara, T., Sugai, M.
(2002). Increased Glycan Chain Length Distribution and Decreased Susceptibility to Moenomycin in a Vancomycin-Resistant Staphylococcus aureus Mutant. Antimicrob. Agents Chemother.
46: 75-81
[Abstract]
[Full Text]
-
Finan, J. E., Archer, G. L., Pucci, M. J., Climo, M. W.
(2001). Role of Penicillin-Binding Protein 4 in Expression of Vancomycin Resistance among Clinical Isolates of Oxacillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother.
45: 3070-3075
[Abstract]
[Full Text]